Medical College of Wisconsin researchers in Milwaukee have shown for the first time that thrombopoietin (TPO), a naturally occurring protein being developed as a pharmaceutical to increase platelet count in cancer patients during chemotherapy, can also protect the heart against injury during a heart attack.
The study, led by John E. Baker PhD, professor of pediatric surgery in the division of cardiothoracic surgery, was published in the January 2008 issue of Cardiovascular Research. The importance of these findings was underscored in an accompanying editorial.
Currently there are no therapies available to directly protect the heart against the damaging effects of a heart attack. Dr. Baker’s team has shown that administering a single dose of TPO to rats during a heart attack decreased the extent of permanent muscle damage to the heart and increased the ability of the heart to function afterwards, when compared with no drug treatment. Additionally, they found that a single cardioprotective treatment with TPO did not increase platelet count. This novel finding suggests the cardioprotective actions of TPO are separate from its ability to increase platelet count.
Dr. Baker has submitted a US and worldwide patent application on the tissue protective properties of TPO. Dr. Baker’s discovery is licensed to Cardiopoietis, a Wisconsin LLC, formed to develop drugs for the treatment of heart attacks.
TPO is a hormone which is naturally produced by the liver and kidney. Dr. Baker’s investigative team had previously shown that erythropoietin, a protein and pharmaceutical currently in clinical use to treat anemia in end-stage kidney disease, protects the rat heart against injury during a heart attack. They found that although erythropoietin and TPO have separate functional roles, there were similarities in the structures of the two proteins that suggested TPO may have protective properties similar to erythropoietin.
“We hypothesized that a single treatment with TPO during a heart attack would be sufficient to protect the heart from injury,” says Dr. Baker. “Our results suggest that TPO directly protects the heart and may represent a novel approach for the treatment of acute heart attack.”
Source: Medical College of Wisconsin
Related stories:
New guidelines for treating rheumatoid arthritis
Proven combinations of medicines and the introduction of new anti-arthritis drugs have significantly improved the treatment of rheumatoid arthritis (RA), according to guidelines issued by the American College of Rheumatology and co-authored by physicians at the University of Alabama at Birmingham (UAB).
Minimally invasive treatment improves male fertility
A minimally invasive treatment for a common cause of male infertility can significantly improve a couple's chances for pregnancy, according to a new study published in the August issue of Radiology. The study, conducted at the University of Bonn in Germany, also found that the level of sperm motility prior to treatment is a key predictor of success.
Still puzzling: Best care for the frail and elderly with coronary artery disease
A new study from Duke University Medical Center finds that patients treated solely with medications after suffering from chest pain, heart attack or coronary artery disease are more likely to die during the first year following their initial hospitalization.
Heart attack not a death sentence
Survivors of cardiac arrest who received intensive care can expect long-term quality of life at reasonable expense to the health care system. Research published today in BioMed Central's open access journal
Critical Care is the first to show that the allocation of resources to the treatment of heart attack patients is equally as justified as the treatment of other intensive care patient groups.
First human use of new device to make arrhythmia treatment safer
On June 16, 2008, Barbara Ganschow of Palatine, IL, became the first person in the world to be successfully treated with a new device designed to make it safer and easier for heart specialists to create a hole in the cardiac atrial septum. The hole, created by the NRGTM Transseptal Needle, allows cardiac catheters to cross from the right side of the heart to the left side.
Study finds high-dose HBO2 therapy extends survival window after cardiopulmonary arrest
A ground-breaking study by researchers at the School of Medicine at LSU Health Sciences Center New Orleans published in the August 2008 issue of
Resuscitation has major implications for the #1 cause of death of Americans -- sudden cardiac arrest.
Coronary heart disease patients live longer, but not always happier, lives
Better treatments have improved survival in people with coronary heart disease, but the quality of those extra years may be less than ideal, according to research reported in Circulation: Journal of the American Heart Association.
An alternative to chemotherapy: Nanoparticles tackle pediatric brain tumors
An interdisciplinary team of researchers at Washington University in St. Louis, led by Karen L. Wooley, Ph.D., James S. McDonnell Distinguished University Professor in Arts & Sciences, is a step closer to delivering cancer-killing drugs to pediatric brain tumors, similar to the tumor that Senator Ted Kennedy is suffering from.